Rhumbline Advisers Mustang Bio, Inc. Transaction History

Rhumbline Advisers

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.58 - $1.13 $41,352 - $80,565	-71,297 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$0.73 - $1.81 $6,648 - $16,485	-9,108 Reduced 11.33%	71,297 $72,000
Q4 2021 Feb 10, 2022	BUY	$1.66 - $2.64 $6,845 - $10,887	4,124 Added 5.41%	80,405 $133,000
Q3 2021 Nov 12, 2021	BUY	$2.58 - $3.36 $5,652 - $7,361	2,191 Added 2.96%	76,281 $205,000
Q2 2021 Aug 05, 2021	BUY	$2.7 - $3.81 $106,261 - $149,946	39,356 Added 113.31%	74,090 $246,000
Q1 2021 May 06, 2021	BUY	$3.02 - $5.16 $5,919 - $10,113	1,960 Added 5.98%	34,734 $115,000
Q4 2020 Feb 10, 2021	BUY	$2.66 - $4.18 $16,944 - $26,626	6,370 Added 24.13%	32,774 $124,000
Q3 2020 Nov 12, 2020	SELL	$3.01 - $3.88 $14,718 - $18,973	-4,890 Reduced 15.63%	26,404 $83,000
Q2 2020 Aug 13, 2020	BUY	$2.33 - $4.6 $4,433 - $8,753	1,903 Added 6.47%	31,294 $100,000
Q4 2019 Feb 05, 2020	BUY	$2.57 - $4.08 $2,056 - $3,264	800 Added 2.8%	29,391 $120,000
Q3 2019 Oct 23, 2019	SELL	$2.74 - $4.65 $753 - $1,278	-275 Reduced 0.95%	28,591 $93,000
Q2 2019 Aug 14, 2019	BUY	$2.66 - $6.28 $25,317 - $59,773	9,518 Added 49.19%	28,866 $106,000
Q1 2019 May 01, 2019	SELL	$2.95 - $5.61 $1,298 - $2,468	-440 Reduced 2.22%	19,348 $66,000
Q4 2018 Jan 31, 2019	BUY	$2.3 - $5.78 $15,156 - $38,090	6,590 Added 49.93%	19,788 $58,000
Q3 2018 Nov 07, 2018	SELL	$5.71 - $7.58 $6,994 - $9,285	-1,225 Reduced 8.49%	13,198 $79,000
Q2 2018 Aug 06, 2018	BUY	$6.68 - $11.0 $96,345 - $158,653	14,423 New	14,423 $99,000

415K

Ticker MBIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,222,000
Market Cap $22.1M
Description
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.